Accordingly, T-PLL patients are characterized by the overexpression of TCL1A/B genes and other recurrent lesions in MTCP1, ATM, MYC, and STAT pathways, all of which play a crucial role in cell survival, proliferation, and oncogenic processes [41]. This evidence concerns the gene TCL1A and prolymphocytic leukemia.